Novartis AG (NYSE:NVS)
| 87.36 Delayed Data As of Nov 29 |  -0.32 / -0.36%Today’s Change | 74.09 Today|||52-Week Range 94.26 | -0.13% Year-to-Date |
Latest NVS News | Press Releases
| Incyte (INCY) Outperforms YTD: Will the Momentum Continue? Nov 25 / Zacks.com - Paid Partner Content | 2 Top Biotech Stocks to Buy Right Now Nov 19 / MotleyFool.com - Paid Partner Content |
| Novartis (NVS) Set to Advance Malaria Drug Into Phase III Nov 24 / Zacks.com - Paid Partner Content | Novartis (NVS) Reportedly Looking to Sell Its Business Units Nov 17 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 87.68 |
| Today’s open | 87.76 |
| Day’s range | 87.28 - 88.01 |
| Volume | 1,403,834 |
| Average volume (3 months) | 2,240,423 |
| Market cap | $188.7B |
Data as of 4:00pm ET, 11/29/2022
Growth & Valuation
| Earnings growth (last year) | +202.15% |
| Earnings growth (this year) | -4.57% |
| Earnings growth (next 5 years) | +4.06% |
| Revenue growth (last year) | +6.10% |
| P/E ratio | 9.0 |
| Price/Sales | 3.83 |
| Price/Book | 2.90 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.13 | -0.19% |
| NVONovo Nordisk | +0.12 | +0.10% |
| BMYBristol-Myers Squibb | -0.16 | -0.20% |
| SNYSanofi | +0.33 | +0.72% |
Data as of 4:00pm ET, 11/29/2022
Financials
| Next reporting date | February 1, 2023 |
| EPS forecast (this quarter) | $1.37 |
| Annual revenue (last year) | $51.6B |
| Annual profit (last year) | $24.0B |
| Net profit margin | 46.53% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Basel, Basel-stadt (basle Town) |
Forecasts
